CLAIMS

What is Claimed:

1. Use of Compound I, or a pharmaceutically acceptable salt or solvate thereof,



I

in the manufacture of a medicament for the treatment of cancer in a subject, wherein the Compound I, or a pharmaceutically acceptable salt or solvate thereof is to be administered to the subject, and wherein the subject has a *PALB2* mutation and/or a *BRCA2* mutation.

2. The use of claim 1, wherein the subject has a *PALB2* mutation.

3. The use of claim 1, wherein the subject has a *BRCA2* mutation.

4. The use of claim 1, wherein the subject has a *PALB2* mutation and a *BRCA2* mutation.

5. The use of any one of claims 1-4, wherein the cancer is a hematologic malignancy, colorectal cancer, breast cancer, lung cancer, liver cancer, ovarian cancer, cervical cancer, Ewing's sarcoma, pancreatic cancer, cancer of the lymph nodes, colon cancer, prostate cancer, brain cancer, bone cancer, cancer of the head and neck, skin cancer, kidney cancer, osteosarcoma, cancer of the heart, uterine cancer, gastrointestinal malignancies, or carcinomas of the larynx and oral cavity.

6. The use of claim 5, wherein the cancer is breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer.

7. The use of claim 5, wherein the hematologic malignancy is selected from leukemia, lymphoma, myeloma, and multiple myeloma.

8. The use of any one of claims 1-7, wherein the Compound I or a pharmaceutically acceptable salt thereof is to be administered at a dose ranging from about 50 mg to about 1,000 mg of the Compound I or a pharmaceutically acceptable salt and/or solvate thereof, per body surface area of the subject (m^2).

9. The use of any one of claims 1-8, wherein the Compound I or a pharmaceutically acceptable salt thereof is to be administered in a liquid dosage form prepared from a lyophilized form of the Compound I or a pharmaceutically acceptable salt thereof.

10. The use of any one of claims 1-9, wherein the Compound I or a pharmaceutically acceptable salt thereof is to be administered in a 28-day cycle.

11. The use of claim 10, wherein a dose of the Compound I or a pharmaceutically acceptable salt thereof is to be administered on day 1, day 8, and day 15 of the 28-day cycle.

12. The use of claim 10, wherein a dose of the Compound I or a pharmaceutically acceptable salt thereof is to be administered on day 1 and day 8 of the 28-day cycle.

13. A pharmaceutical composition comprising Compound I, or a pharmaceutically acceptable salt and/or solvate thereof and a pharmaceutically acceptable carrier or excipient,



I

wherein, the composition provides a plasma Compound I AUC_{∞} ranging from about 2,000 ng*hr/mL to about 110,000 ng*hr/mL after a single dose administration of the composition to a human subject at a dose of about 50 mg to about 650 mg of the Compound I or a pharmaceutically acceptable salt and/or solvate thereof, per body surface area of the subject (m^2).

14. The pharmaceutical composition of claim 13, wherein the composition provides a plasma Compound I C_{max} ranging from about 200 ng/mL to about 6,000 ng/mL.

15. The pharmaceutical composition of claim 13 or 14, wherein the composition provides a plasma Compound I T_{max} ranging from about 0.3 hour to about 2.0 hours.

16. The pharmaceutical composition of any one of claims 13-15, wherein the composition is a liquid composition prepared with a lyophilized form of Compound I or a pharmaceutically acceptable salt and/or solvate thereof.

17. Use of a therapeutically effective amount of a pharmaceutical composition of any one of claims 13-16 in the manufacture of a medicament for the treatment or amelioration

of cell proliferation disorder in a subject in need thereof, wherein the pharmaceutical composition is administered to the subject.

18. The use of claim 17, wherein the cell proliferation disorder is a hematologic malignancy, colorectal cancer, breast cancer, lung cancer, liver cancer, ovarian cancer, cervical cancer, Ewing's sarcoma, pancreatic cancer, cancer of the lymph nodes, colon cancer, prostate cancer, brain cancer, bone cancer, cancer of the head and neck, skin cancer, kidney cancer, osteosarcoma, cancer of the heart, uterine cancer, gastrointestinal malignancies, or carcinomas of the larynx and oral cavity.

19. The use of claim 18, wherein the cancer is breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer.

20. The use of claim 18, wherein the hematologic malignancy is selected from leukemia, lymphoma, myeloma, and multiple myeloma.

21. The use of any one of claims 18-20, wherein the cancer is a *PALB2*-mutated cancer.

22. The use of any one of claims 18-21, wherein the cancer is a *BRCA2*-mutated cancer.

23. The use of any one of claims 17-22 wherein the subject is to be administered the Compound I or a pharmaceutically acceptable salt thereof at a dose ranging from about 50 mg to about 1,000 mg of the Compound I or a pharmaceutically acceptable salt and/or solvate thereof, per body surface area of the subject (m^2).

24. The use of any one of claims 17-23, wherein the composition is to be administered in a 28-day cycle.

25. The use of claim 24, wherein a dose of the Compound I or a pharmaceutically acceptable salt thereof is to be administered on day 1, day 8, and day 15 of the 28-day cycle.

26. The use of claim 24, wherein a dose of the Compound I or a pharmaceutically acceptable salt thereof is to be administered on day 1 and day 8 of the 28-day cycle.

27. Use of a therapeutically effective amount of a pharmaceutical composition of any one of claims 13-16 in the manufacture of a medicament for the inhibition of Pol I transcription in a subject in need thereof, wherein the pharmaceutical composition is administered to the subject.

28. Use of a therapeutically effective amount of a pharmaceutical composition of any one of claims 13-16 in the manufacture of a medicament for the stabilization of G-quadruplexes (G4s) in a subject in need thereof, wherein the pharmaceutical composition is administered to the subject.